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Heparin is currently the anticoagulant of choice for the 
prevention and treatment of thrombo-embolic disease in 
pregnancy because it does not cross the placenta.1 The use of 
low-molecular-weight heparin (LMWH) is preferred to 
unfractionated heparin (UFH) as it is associated with a lower 
risk of bleeding, osteoporosis, heparin-induced 
thrombocytopenia (HIT) and hypersensitivity reactions.2-5 
Fondaparinux is a valuable alternative to LMWH during 
pregnancy in patients with heparin-induced skin reactions 
and/or HIT.
Heparin-induced skin reactions are well documented with 
subcutaneously administered UFH; however they occur rarely 
(at reported rates between 0.3% and 0.6%) in association 
with LMWH.6,7  Reports indicate that heparin-associated skin 
reactions are more common in pregnancy.8  HIT can present as 
isolated skin manifestations and therefore must be excluded 
when skin lesions develop.1 The skin reaction may resolve 
when LMWH preparations are interchanged.9,10  However, 
when broad cross-reactivity between heparins develops, the 
choice of alternative anticoagulants is limited. In the majority 
of patients with skin necrosis, HIT and thrombosis may occur 
if heparin is not discontinued. Fondaparinux and other new 
direct thrombin inhibitors are alternative therapies in patients 
known to be hypersensitive to LMWH preparations. However, 
these agents have not been formally evaluated during 
pregnancy primarily because they cross the placenta.
Fondaparinux was used successfully in a young pregnant 
woman who presented with severe pulmonary thrombo-
embolic disease at 16 weeks’ gestation with a twin pregnancy. 
She developed a hypersensitivity reaction to two LMWH 
preparations, viz. enoxaparin and nadroparin.
Case study
A 30-year-old woman presented with severe pulmonary 
thrombo-embolic disease at 16 weeks’ gestation with a twin 
pregnancy. Her previous two pregnancies had been uneventful. 
She had been treated with an ovulation stimulant, clomifene 
(Clomid) 50 mg. She gave a history of urticaria pigmentosa 
in infancy, which is associated with an increased risk of 
hypersensitivity reactions. 
She had no family history of thrombophilia and no history 
of allergy to UFH or LMWH, and was started on therapeutic 
enoxaparin (Clexane) 60 mg twice a day subcutaneously. 
Symptoms improved, her platelet count remained normal, 
and anti-Xa activity was monitored and maintained in the 
therapeutic range. 
About 6 weeks later she developed erythematous, indurated 
lesions at injection sites on her thigh and abdomen (Fig. 1), 
accompanied by intense pruritus. There was no decrease in the 
platelet count. She was changed to nadroparin (Fraxiparine) 
0.3 ml daily subcutaneously with a local cortisone cream. The 
skin reaction improved with no new rashes at the injection 
sites (Fig. 2), but 3 weeks later she developed a severe skin 
reaction. At this time (28 weeks’ gestation), intramuscular 
betamethasone (Celestone) 4 mg/ml was given for fetal lung 
maturity, which resulted in partial resolution and relief from 
the pruritus. The skin reaction however recurred. Nadroparin 
was stopped and fondaparinux 2.5 mg was started daily. Anti-
Xa activity was not monitored (dose adaptation is not required 
for patients receiving a fixed dose of 2.5 mg once daily).11 
Treatment was continued uneventfully until healthy twin 
girls (birth weights 2 200 g and 2 400 g) were delivered by 
caesarean section. Cord blood fondaparinux concentration 
and anti-Xa activity were not measured in the newborn twins 
because fondaparinux was not given to the mother during the 
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24 hours preceding caesarean section and cord blood was sent 
for stem cell harvesting. 
Post partum she is fully warfarinised and is well.
Discussion
Skin complications occur more frequently with long-term use 
of LMWH.12 This reaction, which in this case presented as 
tender erythematous lesions at the injection sites, probably 
represents a moderate delayed type IV skin reaction. These 
lesions may progress to necrotic patches. In some cases, 
histological examination of the skin lesions has shown 
thrombosis of the cutaneous vessels associated with HIT.13 
In most patients with skin necrosis, heparin-induced 
thrombocytopenia and thrombosis (HIT type II) may occur if 
heparin is not discontinued.14 However, in pregnancy choices 
of alternative anticoagulants are limited. 
In South Africa only enoxaparin and nadroparin are 
recommended in pregnancy because anti-Xa levels can be 
monitored. Dalteparin is currently not recommended, as 
accurate anti-Xa monitoring is not available locally.
Vitamin K antagonists are generally contraindicated because 
they cross the placenta and are associated with a significant 
risk of brain damage in the fetus secondary to intracerebral 
haemorrhage, as well as teratogenesis in the first trimester.15
The successful use of hirudin derivatives has been reported 
in one case of pregnancy with heparin allergy. No adverse fetal 
outcome was demonstrated in animal models.16
Danaparoid, a low-molecular-weight heparinoid with low 
placental permeability, is considered by some to be the drug of 
choice for heparin allergy in pregnancy,12,17-19 but is currently 
not available in South Africa and was therefore not an option 
in this patient.
Fondaparinux and other new direct thrombin inhibitors 
have not been formally evaluated during pregnancy, but 
large orthopaedic clinical trials have shown it to be as safe 
and effective as LMWH.20,21  Fondaparinux is a synthetic 
pentasaccharide that inhibits factor Xa, and therefore could 
be used in patients known to be hypersensitive to LMWH 
preparations.11 In vitro studies have failed to demonstrate cross-
reactivity with fondaparinux in LMWH-intolerant patients. 
Reports of successful use of fondaparinux in patients who 
experienced hypersensitivity reactions to LMWH also suggest 
that cross-reactivity does not occur in vivo.22, 23 Similarly, other 
studies indicate that fondaparinux is associated with a low risk 
of HIT.24 
An advantage of fondaparinux is that it produces a 
predictable anticoagulant response and can be administered 
without anticoagulation monitoring. Alternatively, anti-Xa 
levels can be measured using assays similar to those used to 
monitor LMWH.25 A recently published report indicated that 
fondaparinux does cross the placental barrier.26 The anti-Xa 
activity detected in the umbilical cord blood was below the 
level required to have a therapeutic anticoagulant effect. It is 
not known whether fondaparinux potentially has a harmful 
effect on the fetus, and its use should be restricted to patients 
with either severe allergic reaction to heparin, as in our case, or 
HIT. 
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